Recurring Diverticulitis clinical trials

Explore recruiting recurring diverticulitis clinical trials.

Recruiting recurring diverticulitis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Recurring Diverticulitis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase IIa randomized, controlled, open-label clinical trial to assess the efficacy, safety, and tolerability of the investigational medicinal product MBK-01, FSPIM (Full Spectrum & Purified Intestinal Microbiota) oral capsules, as well as to determine the optimal dosage in the treatment of patients with recurrent diverticulitis (DIREBIOT).

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Recurring Diverticulitis trials by city

Recurring Diverticulitis in Toronto Recurring Diverticulitis in Vancouver Recurring Diverticulitis in Montreal Recurring Diverticulitis in Calgary Recurring Diverticulitis in Edmonton Recurring Diverticulitis in Ottawa Recurring Diverticulitis in Winnipeg Recurring Diverticulitis in Quebec City Recurring Diverticulitis in Hamilton Recurring Diverticulitis in Kitchener Recurring Diverticulitis in London Recurring Diverticulitis in Halifax Recurring Diverticulitis in New York Recurring Diverticulitis in Los Angeles Recurring Diverticulitis in Chicago Recurring Diverticulitis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease